Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

ExploringTrades Aug. 4 at 7:25 PM

Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $ESPR $APP Anyone holding?

0 · Reply

Enjoyycall Aug. 3 at 11:37 PM

$ESPR

0 · Reply

josh23941 Aug. 3 at 5:46 PM

$ESPR

0 · Reply

BillyBob1337 Jul. 31 at 9:41 PM

$ESPR $DENN same tactic with shorts...thoughts?

0 · Reply

Gregg617notEsprguy Jul. 29 at 3:50 PM

$ESPR posted this a few days ago my new play

2 · Reply

fortyeight Jul. 28 at 7:36 PM

$ESPR Because it has a corrupt BOD.

0 · Reply

Enjoyycall Jul. 28 at 2:22 PM

$ESPR Boom, more coming.

0 · Reply

Spaceequiped Jul. 27 at 2:26 PM

$ESPR its coming

1 · Reply

Pukkaa56 Jul. 27 at 1:25 PM

$ESPR BMEA CRDL OSTX

0 · Reply

Enjoyycall Jul. 25 at 5:10 AM

$ESPR when they knock

0 · Reply

Esperion Therapeutics Transcript: EGM 2026

Jun 16, 2026, 8:00 AM EDT - 7 weeks ago

Esperion Therapeutics Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Proxy statement: Proxy filing

May 28, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Transcript: AGM 2026

May 26, 2026, 8:00 AM EDT - 2 months ago

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

May 14, 2026, 4:30 PM EDT - 2 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 13, 2026, 8:00 AM EDT - 2 months ago

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

May 8, 2026, 7:00 AM EDT - 3 months ago

Esperion Therapeutics Quarterly report: Q1 2026

May 4, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Proxy statement: Proxy filing

May 1, 2026, 7:37 AM EDT - 3 months ago

Archimed to take Esperion Therapeutics private in $1.1 billion deal

May 1, 2026, 7:00 AM EDT - 3 months ago

Esperion to be Acquired by ARCHIMED

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Esperion to Report First Quarter 2026 Financial Results on May 7

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 9:30 AM EDT - 4 months ago

Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 2, 2026, 4:05 PM EDT - 4 months ago

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Apr 2, 2026, 4:00 PM EDT - 4 months ago

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Mar 16, 2026, 6:30 AM EDT - 5 months ago

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

Mar 11, 2026, 8:25 AM EDT - 5 months ago

Esperion Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Esperion Therapeutics Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Esperion Therapeutics Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Esperion Therapeutics Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Esperion Therapeutics Slides: Q4 2025

Mar 10, 2026, 6:00 AM EDT - 5 months ago

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Esperion Therapeutics Slides: Corporate presentation

Mar 3, 2026, 8:00 AM EST - 5 months ago

Esperion Therapeutics Transcript: M&A announcement

Mar 3, 2026, 8:00 AM EST - 5 months ago

Esperion Therapeutics Press release: M&A announcement

Mar 3, 2026, 8:00 AM EST - 5 months ago

Esperion Therapeutics Slides: M&A announcement

Mar 3, 2026, 6:00 AM EST - 5 months ago

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Feb 18, 2026, 8:00 AM EST - 5 months ago

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Feb 17, 2026, 8:00 AM EST - 6 months ago

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Jan 14, 2026, 5:15 PM EST - 7 months ago

Esperion Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 5:15 PM EST - 7 months ago

Esperion Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 6:00 PM EST - 7 months ago

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 3:30 PM EST - 8 months ago

Esperion Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 7:00 AM EST - 9 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov 18, 2025, 3:00 AM EST - 9 months ago

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 2:00 PM EST - 9 months ago

Esperion Therapeutics Transcript: KOL Event

Nov 11, 2025, 2:00 PM EST - 9 months ago

Esperion Therapeutics Slides: KOL Event

Nov 6, 2025, 8:00 AM EST - 9 months ago

Esperion Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

Esperion Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

Esperion Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

Esperion Therapeutics Slides: Q3 2025

Nov 4, 2025, 8:00 AM EST - 9 months ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Oct 7, 2025, 9:29 PM EDT - 10 months ago

Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 10 months ago

Esperion Announces Proposed Public Offering of Common Stock

Oct 3, 2025, 8:00 AM EDT - 10 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Sep 19, 2025, 8:00 AM EDT - 11 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Sep 8, 2025, 2:00 PM EDT - 11 months ago

Esperion Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:45 AM EDT - 11 months ago

Esperion Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 29, 2025, 8:00 AM EDT - 1 year ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 1 year ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 1 year ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 9, 2025, 10:40 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 1:25 PM EDT - 1 year ago

Esperion Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 20, 2025, 10:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 12:30 PM EDT - 1 year ago

Esperion Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 6:30 AM EDT - 1 year ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Press release: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Status Update

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Registration statement: Registration Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 7, 2025, 8:45 AM EDT - 1 year ago

Esperion Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Annual report: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings release: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Slides: Q4 2024

Mar 4, 2025, 6:00 AM EST - 1 year ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 1 year ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: KOL Event

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Slides: KOL Event

Jan 15, 2025, 6:45 PM EST - 1 year ago

Esperion Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Esperion Therapeutics Slides: FY 2025

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 5, 2024, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 11:30 AM EST - 1 year ago

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 10:30 AM EST - 1 year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Slides: Q3 2024

Nov 7, 2024, 6:00 AM EST - 1 year ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 4, 2024, 8:00 AM EST - 1 year ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Sep 25, 2024, 4:30 PM EDT - 2 years ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 19, 2024, 10:55 AM EDT - 2 years ago

Esperion Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2024, 10:55 AM EDT - 2 years ago

Esperion Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 2 years ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Aug 26, 2024, 8:00 AM EDT - 2 years ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Slides: Q2 2024

Aug 12, 2024, 6:00 AM EDT - 2 years ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Esperion Therapeutics Slides: Corporate Presentation

Jul 16, 2024, 8:00 AM EDT - 2 years ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

ExploringTrades Aug. 4 at 7:25 PM

0 · Reply

Enjoyycall Aug. 3 at 11:37 PM

$ESPR

0 · Reply

josh23941 Aug. 3 at 5:46 PM

$ESPR

0 · Reply

BillyBob1337 Jul. 31 at 9:41 PM

$ESPR $DENN same tactic with shorts...thoughts?

0 · Reply

Gregg617notEsprguy Jul. 29 at 3:50 PM

$ESPR posted this a few days ago my new play

2 · Reply

fortyeight Jul. 28 at 7:36 PM

$ESPR Because it has a corrupt BOD.

0 · Reply

Enjoyycall Jul. 28 at 2:22 PM

$ESPR Boom, more coming.

0 · Reply

Spaceequiped Jul. 27 at 2:26 PM

$ESPR its coming

1 · Reply

Pukkaa56 Jul. 27 at 1:25 PM

$ESPR BMEA CRDL OSTX

0 · Reply

Enjoyycall Jul. 25 at 5:10 AM

$ESPR when they knock

0 · Reply

Enjoyycall Jul. 25 at 4:14 AM

$ESPR “Challenge accepted!” Proceeds to lose for every post till he runs and try’s to hide🫶✈️🇺🇸

1 · Reply

NEWBIGTECH Jul. 24 at 7:00 PM

Yeah. They screwed themselves. I have about 0 amount of confidence in $ICU and their management. A lot like $ESPR. GARBAGE.

0 · Reply

__LucidDreamer__ Jul. 24 at 6:33 PM

$ESPR Esperion investors!!! Come on in over at Radiopharm Theranostics…the water is just fine here… It is the ESPR game all over…promising drugs, dilution, pops and drops. And no DJ fraudster claiming a switch will be pulled. Just need commonsense and balls.

0 · Reply

RDarron Jul. 24 at 11:56 AM

$ESPR

0 · Reply

ExploringTrades Jul. 23 at 10:52 PM

$ESPR $SQQQ Bulls will bank

0 · Reply

Spaceequiped Jul. 23 at 6:21 PM

$ESPR DJ was and is the fraud. He is trying to hide. 🇺🇸

1 · Reply

biotech_sellout Jul. 23 at 1:30 PM

$ESPR The three stooges of pump n dump: Canyon, Brinks, BRDA. All now humping for RZLV.

0 · Reply

biotech_sellout Jul. 23 at 1:25 PM

$ESPR And to further piece the puzzle as if there is a connection between Brinks and Buyoutrumors on twitter, there is a good case to be made that both are one in the same person or group that tries to pump and dump the same stock. First ESPR and now RZLV. Keep in mind that BRDA has really focused on just one stock, ESPR, and got that very wrong. Let's hope those involved with those two accounts get a really bad case of anal cancer.

0 · Reply

biotech_sellout Jul. 23 at 9:58 AM

$ESPR FWIW, pump and dump artist Brinks has come out from the pile of dung he hides under to pump a new symbol.

0 · Reply

Enjoyycall Jul. 23 at 7:59 AM

$ESPR posting $12B in valuation and sharing a bs spreadsheet makes you a genius. Owned ….he was and is a fraud. Too bad he had to run and hide

0 · Reply

Enjoyycall Jul. 23 at 7:21 AM

$ESPR “I said to myself, self”. This board, many

0 · Reply

Market Cap	819.46M
Revenue (ttm)	403.14M
Net Income (ttm)	-22.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5.63%
Debt to Equity Ratio	-0.50

Volume	59,090,402
Avg Vol	17,213,020
Day's Range	N/A - N/A
Shares Out	257.69M
Stochastic %K	75%
Beta	1.07
Analysts	Hold
Price Target	$2.97